Why Cannabinoids Work Best Together
March 7th, 2017
News, Top News
Most people can only name one or two cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), but there are over 100 different cannabinoids within the cannabis plant. While a lot of research is focused on the effects of individual cannabinoids, emerging evidence suggests that there may be important synergies between these cannabinoids. New therapeutics that combine cannabinoids in innovative ways could dramatically improve outcomes.
In this article, we will take a look at why cannabinoids work best together and how companies like GB Sciences Inc. (OTCQB: GBLX) are taking advantage of these dynamics.
Researches have started to notice that cannabinoids tend to have an ‘entourage effect’, which means they tend to work better when combined rather than in isolation.
THC-only pharmaceuticals, like Marinol (dronabinol) and Cesamet (nabilone), have experienced limited efficacy. In fact, less than 2% of patients in a 2011 survey preferred THC-only pharmaceuticals over inhaled or infused delivery methods. CBD-only therapies have proven much more beneficial – particularly with conditions like epilepsy – but emerging evidence has shown that combinations of these cannabinoids could be even more beneficial.
Dr. Than Russo, M.D., a neurologist who has become an expert in cannabinoids, notes many of these synergies in his study “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects”, which details many cannabinoid interactions.
There are also over 100 other cannabinoids in the cannabis plant that work together to reach therapeutic goals. For example, CBC is the third most common cannabinoid in the cannabis plant and works with THC to fight inflammation. THCv is another cannabinoid that has been shown to mitigate some of the negative psychoactive impacts of THC. These kinds of combinations could produce safer and more effective therapies targeting many conditions.
Taking a Holistic Approach
GB Sciences has embraced the complexity of both the cannabis plant and endocannabinoid system. By taking a holistic approach, the company aims to leverage the natural interactions between hundreds of cannabinoids, terpenes, and other phytochemicals within the cannabis plant on many different receptors within the endocannabinoid system. These targets are identified using a high-throughput screening system that incorporates cellular and animal models of disease, as well as in silico experiments run with sophisticated algorithms.
Recently, the company filed a series of patents covering cannabinoid-containing complex mixtures, addressing areas like neuronal protection (Parkinson’s, Alzheimer’s, Huntington’s, etc.) and inflammation (arthritis, IBS, Crohn’s, asthma, etc.). The company also licensed an existing patent from Makai Biotechnology covering therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies of the cardiovascular system.
With these patents in place, GB Sciences recently engaged a California-based contract research organization that will help complete pre-clinical trials on animals, file an Investigational New Drug application to begin human testing, and conduct its first human clinical trials. These efforts will accelerate the time-to-market and ensure that the company is adhering to best practices when executing clinical trials covering these enormous multi-billion dollar markets with significant unmet needs.
Finally, the company is taking a very clinical approach to the market to ensure the highest levels of standardization for both safety and efficacy reasons. Its manufacturing facility features standardized cultivation and extraction techniques designed to produce products with refined clinical properties, and it is applying for ISO certification for the facility. These levels of standardization are necessary for regulatory approvals as it moves into clinical trials.
The cannabis plant is more complex than many people realize with hundreds of different cannabinoids, terpenes, and phytochemicals. The interactions between these different components are just now starting to be understood and could unlock significant therapeutic potential over the long run. GB Sciences Inc. (OTCQB: GBLX) aims to capitalize on these interactions and develop leading drugs targeting multi-billion dollar markets.
In the meantime, the company also owns and operates a licensed cultivation facility in Nevada that should help generate near-term revenue to offset its research and development costs while providing it with its own high-quality, standardized products for clinical trials.
For more information, visit the company’s website at www.growblox.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.